PRESS RELEASES
StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device
Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...
Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Stemedica Cell Technologies, Inc. ("Stemedica"), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its study entitled "A Phase II,...
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
SAN DIEGO, California, May 24, 2021 – Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the...
FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients
SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the...
Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients
TOLEDO, Ohio, July 28, 2020 – ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug...
FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHN’S HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica,...
Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke
San Francisco, CA – CONGRESS OF NEUROLOGICAL SURGEONS October 19, 2019 – October 23, 2019 – Study sponsor Stemedica Cell Technologies, Inc., a global biotechnology company that uses cGMP manufactured, ischemia-tolerant (itMSCs), bone marrow derived, allogeneic...
Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal
Study Sponsored by Stemedica Cell Technologies, Inc. SAN DIEGO, Calif. – (September 30, 2019) – Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis...
Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke
Abstract Background and Purpose Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous...
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke - itMSCs were safe and well tolerated in the study - - Results of the study are supportive of advancing clinical program - - Plans are underway to...